JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Angiotensin I
/ therapeutic use
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Antiviral Agents
/ therapeutic use
Azetidines
/ therapeutic use
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
/ drug therapy
Disease Progression
Gene Expression Regulation
Host-Pathogen Interactions
/ genetics
Humans
Janus Kinases
/ antagonists & inhibitors
Methotrexate
/ therapeutic use
Molecular Targeted Therapy
/ methods
Pandemics
Peptide Fragments
/ therapeutic use
Peptidyl-Dipeptidase A
/ genetics
Pneumonia, Viral
/ drug therapy
Purines
Pyrazoles
Receptor, Angiotensin, Type 1
/ genetics
SARS-CoV-2
STAT Transcription Factors
/ antagonists & inhibitors
Signal Transduction
/ genetics
Sulfonamides
/ therapeutic use
Angiotensin receptor blocker
Angiotensin-converting enzyme inhibitor
Bricitinib
Cytokine
JAK inhibitors
JAK-STAT pathway
Methotrexate
Journal
International archives of allergy and immunology
ISSN: 1423-0097
Titre abrégé: Int Arch Allergy Immunol
Pays: Switzerland
ID NLM: 9211652
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
28
04
2020
pubmed:
12
5
2020
medline:
23
6
2020
entrez:
12
5
2020
Statut:
ppublish
Résumé
After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries. However, more studies are needed to clarify the efficacy of these therapeutics. Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy.
Identifiants
pubmed: 32392562
pii: 000508247
doi: 10.1159/000508247
pmc: PMC7270061
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Antiviral Agents
0
Azetidines
0
Peptide Fragments
0
Purines
0
Pyrazoles
0
Receptor, Angiotensin, Type 1
0
STAT Transcription Factors
0
Sulfonamides
0
Angiotensin I
9041-90-1
Janus Kinases
EC 2.7.10.2
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
angiotensin I (1-7)
IJ3FUK8MOF
baricitinib
ISP4442I3Y
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-475Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 S. Karger AG, Basel.
Références
Cardiorenal Med. 2020;10(2):69-84
pubmed: 32062648
N Engl J Med. 2014 Jun 19;370(25):2377-86
pubmed: 24941177
Clin Exp Immunol. 1999 Jan;115(1):42-55
pubmed: 9933419
Ther Clin Risk Manag. 2019 Feb 13;15:275-284
pubmed: 30858707
Virus Res. 2008 Apr;133(1):13-9
pubmed: 17374415
Leuk Res. 2018 Aug;71:82-88
pubmed: 30025280
Clin Rheumatol. 2018 Sep;37(9):2381-2390
pubmed: 30078086
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):413-9
pubmed: 21436210
J Leukoc Biol. 2019 Nov;106(5):1063-1068
pubmed: 31313387
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Ann Rheum Dis. 2015 Feb;74(2):333-40
pubmed: 25431052
J Clin Invest. 2019 Jul 29;129(9):3625-3639
pubmed: 31355779
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i4-i16
pubmed: 30806710
Cell Commun Signal. 2017 Jun 21;15(1):23
pubmed: 28637459
J Virol. 2007 Aug;81(16):8722-9
pubmed: 17522231
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Atherosclerosis. 2007 Sep;194(1):125-33
pubmed: 17109863
PLoS One. 2015 Jul 01;10(7):e0130078
pubmed: 26131691
Nat Rev Rheumatol. 2016 Jan;12(1):25-36
pubmed: 26633291
Am Rev Respir Dis. 1989 Mar;139(3):682-7
pubmed: 2923370
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
F1000Res. 2020 Jan 31;9:72
pubmed: 32117569
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Leuk Res. 2017 Oct;61:89-95
pubmed: 28934680
J Clin Oncol. 2011 Mar 1;29(7):789-96
pubmed: 21220608
Am J Hematol. 2016 Aug;91(8):E329-30
pubmed: 27145026
J Clin Invest. 2018 Jul 2;128(7):3041-3052
pubmed: 29649002
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
Lancet Infect Dis. 2020 Apr 3;:
pubmed: 32251638
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Arthritis Rheumatol. 2017 Mar;69(3):506-517
pubmed: 27723271
Circ Res. 2017 Jun 23;121(1):43-55
pubmed: 28512108
Front Pharmacol. 2015 Jan 30;6:5
pubmed: 25688208
JAMA. 2020 Feb 21;:
pubmed: 32083643
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
Lancet. 2017 Jul 29;390(10093):457-468
pubmed: 28629665
N Engl J Med. 2016 Mar 31;374(13):1243-52
pubmed: 27028914
Biomark Res. 2013 Jan 16;1(1):5
pubmed: 24252238
Joint Bone Spine. 2019 May;86(3):301-307
pubmed: 30081197
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760